[Antileukemic mechanism of resveratrol in vitro and in mice bearing L1210-tumor].
To elucidate the molecular mechanism of resveratrol against leukemia both in vitro and in vivo. Three kinds of leukemia cell lines, HuT-78, Jurkat and L1210 cells, were used in this study. After different doses of Res treatment, methyl thiazolyl tetrazolium (MTT) colorimetry was used to detect the cell proliferation; apoptosis was detected by flow cytometry; Western blot and immuno-precipitation method were used to detect the Bcl-2 and Bax proteins expression and the activity of phospho-signal transducer and activator of transcription 3 (p-STAT3). Besides, a total of 40 BALB/c mice were randomly divided into untreated group and 12.5, 25 and 50 mg/(kg.d) Res groups. Then, leukemia-bearing model was established by L1210 cells subcutaneous injection. Interleukin-6 (IL-6) was detected to determine the secretion function of T lymphocytes of the mice; the IL-6 mRNA expression in the liver tissue of mice was also detected by reverse transcription-polymerase chain reaction (RT-PCR), and the expression of the p-STAT3 protein was measured by Western blot and immunohistochemical method. The results indicated that resveratrol could inhibit the proliferation of HuT-78, Jurkat and L1210 cells and significantly induce the cell apoptosis. At the same time, the radio of Bcl-2/Bax and expression of p-STAT3 protein were decreased either. Furthermore, resveratrol could reduce the expression of IL-6 mRNA and intracellular content of IL-6, and decrease the expression of p-STAT3 protein in the liver of leukemic mice at a dose-dependent manner. Resveratrol can function as an antileukemic agent through inducing apoptosis, modulating IL-6 and STAT3 both in vitro and in vivo.